Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Medtronic
Harvard Business School
AstraZeneca
McKesson

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR TRIFLURIDINE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Trifluridine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000138 ↗ Herpetic Eye Disease Study (HEDS) I Unknown status National Eye Institute (NEI) Phase 3 1989-05-01 To evaluate the efficacy of topical corticosteroids in treating herpes simplex stromal keratitis in conjunction with topical trifluridine. To evaluate the efficacy of oral acyclovir in treating herpes simplex stromal keratitis in patients receiving concomitant topical corticosteroids and trifluridine. To evaluate the efficacy of oral acyclovir in treating herpes simplex iridocyclitis in conjunction with treatment with topical corticosteroids and trifluridine.
NCT00000635 ↗ Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine Completed Glaxo Wellcome N/A 1969-12-31 To determine the safety, effectiveness, and toxicity of topical (local) trifluridine in treating mucocutaneous (at the nasal, oral, vaginal, and anal openings) Herpes simplex virus ( HSV ) disease that has shown resistance to acyclovir in HIV-infected patients. HSV infection in patients with AIDS is often associated with skin sores and frequent recurrences. Treatment with the drug acyclovir results in healing for most patients, but repeated treatment sometimes results in resistance of the virus to acyclovir. Thus, when this happens, other treatments need to be used. Trifluridine is an antiviral drug that is used for the treatment of Herpes infections that occur in the eye. This study attempts to determine if trifluridine is useful for treating HSV sores that have not healed after treatment with acyclovir.
NCT00000635 ↗ Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 To determine the safety, effectiveness, and toxicity of topical (local) trifluridine in treating mucocutaneous (at the nasal, oral, vaginal, and anal openings) Herpes simplex virus ( HSV ) disease that has shown resistance to acyclovir in HIV-infected patients. HSV infection in patients with AIDS is often associated with skin sores and frequent recurrences. Treatment with the drug acyclovir results in healing for most patients, but repeated treatment sometimes results in resistance of the virus to acyclovir. Thus, when this happens, other treatments need to be used. Trifluridine is an antiviral drug that is used for the treatment of Herpes infections that occur in the eye. This study attempts to determine if trifluridine is useful for treating HSV sores that have not healed after treatment with acyclovir.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Trifluridine

Condition Name

Condition Name for Trifluridine
Intervention Trials
Metastatic Colorectal Cancer 11
Colorectal Cancer 7
Stage IVC Colorectal Cancer AJCC v8 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Trifluridine
Intervention Trials
Colorectal Neoplasms 33
Adenocarcinoma 12
Carcinoma 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Trifluridine

Trials by Country

Trials by Country for Trifluridine
Location Trials
United States 101
Japan 9
Canada 7
Russian Federation 7
United Kingdom 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Trifluridine
Location Trials
California 10
Texas 8
Arizona 8
Florida 7
Minnesota 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Trifluridine

Clinical Trial Phase

Clinical Trial Phase for Trifluridine
Clinical Trial Phase Trials
Phase 3 10
Phase 2 27
Phase 1/Phase 2 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Trifluridine
Clinical Trial Phase Trials
Recruiting 26
Not yet recruiting 8
Completed 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Trifluridine

Sponsor Name

Sponsor Name for Trifluridine
Sponsor Trials
National Cancer Institute (NCI) 13
Taiho Oncology, Inc. 5
Mayo Clinic 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Trifluridine
Sponsor Trials
Other 48
Industry 31
NIH 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Mallinckrodt
Moodys
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.